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Abstract
The RNA-binding and -processing protein TAR DNA-binding protein 43 (TDP-43) is heavily
linked to the underlying causes and pathology of neurodegenerative diseases such as
amyotrophic lateral sclerosis and frontotemporal lobar degeneration. In these diseases,
TDP-43 is mislocalized, hyperphosphorylated, ubiquitinated, aggregated and cleaved. The
importance of TDP-43 cleavage in the disease pathogenesis is still poorly understood. Here
we detail the use of D-sorbitol as an exogenous stressor that causes TDP-43 cleavage in
HeLa cells, resulting in a 35 kDa truncated product that accumulates in the cytoplasm within
one hour of treatment. We confirm that the formation of this 35 kDa cleavage product is
mediated by the activation of caspases. Inhibition of caspases blocks the cleavage of TDP-
43, but does not prevent the accumulation of full-length protein in the cytoplasm. Using D-
sorbitol as a stressor and caspase activator, we also demonstrate that the A90V variant of
TDP-43, which lies adjacent to the caspase cleavage site within the nuclear localization
sequence of TDP-43, confers partial resistance against caspase-mediated generation of the
35 kDa cleavage product.
Introduction
TAR DNA-binding protein 43 (TDP-43) is a ubiquitously expressed nuclear RNA- and DNA-
binding protein [1, 2]. It is involved in a variety of cellular processes, most of which concern
the regulation of RNA, with over 6000 RNA species identified as targets [3]. These processes
include splicing of pre-mRNAs, regulation of mRNA stability and turnover as well as mRNA
trafficking and sequestration of mRNA into transient structures termed stress granules [3–15].
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Furthermore, TDP-43 is a factor in the biogenesis of microRNAs as a component of Drosha
and Dicer complexes, and binds to single-stranded DNA as a transcriptional regulator [1, 16–
20]. In its carboxy-terminus, TDP-43 contains a glycine-rich, prion-like domain that renders
the protein intrinsically prone to aggregation (Fig 1) [21, 22]. Cytoplasmic inclusions of aggre-
gated, ubiquitinated TDP-43 are found in almost all cases of amyotrophic lateral sclerosis
(ALS), the most common form of motor neuron disease, as well as in a subtype of frontotem-
poral lobar degeneration (FTLD) characterized by ubiquitin- and TDP-43-positive inclusions
(FTLD-U) [23, 24]. In addition to nuclear-to-cytoplasmic subcellular relocalization, ubiquiti-
nation and aggregation of TDP-43 in these diseases, other pathological hallmarks include
phosphorylation of TDP-43 at the serine 409/serine 410 site as well as protein truncation, lead-
ing to the formation of C-terminal TDP-43 fragments (CTFs) [25, 26]. These C-terminal frag-
ments are generated through the activation of either caspases or calpains. Thus far, a variety of
potential caspase and calpain cleavage sites have been described (Fig 1) [27–32].
In brain tissues of FTLD-U patients, CTFs of 20–25 kDa are found in insoluble protein
fractions [26], and 35 kDa fragments have been described occasionally in cases of ALS and
FTLD-U [32, 33]. Expression of wild-type or mutant TDP-43 in cell and animal models like-
wise causes the formation of 25 and 35 kDa cleavage products [27, 29, 32, 34–36]. The 35 kDa
fragment is generated by cleavage after Asp89, which lies within the bipartite nuclear localiza-
tion sequence (NLS) of TDP-43, and is specifically generated through activation of the execu-
tioner caspases 3 and 7 [32]. Activated caspase-3 has been described in tissues from ALS and
FTLD patients [37, 38], suggesting its role in the generation of CTFs in human patients. The
clinical relevance of these fragments, however, remains elusive.
Here, we use the sugar alcohol D-sorbitol as a stressor to induce the formation and cyto-
plasmic accumulation of the 35 kDa fragment of TDP-43 in a cell culture system. We show
that the formation of this cleavage product, but not the mislocalization of uncleaved TDP-43
to the cytoplasm, is abrogated by caspase inhibition. We also show that an alanine to valine
amino acid substitution at position 90 (A90V) confers partial resistance to caspase cleavage at
the Asp89 site.
Materials and methods
Cell culture, stress treatments and transfections
HeLa cells (CCL-2, American Type Culture Collection [ATCC]) were cultured in Dulbecco’s
modified Eagle medium (DMEM, Thermo Fisher Scientific) supplemented with 10% fetal
bovine serum (FBS), 100 u/ml penicillin and 100 μg/ml streptomycin. For immunofluores-
cence analysis, cells were grown on coverslips in 24-well plates (Cellstar). For stress experi-
ments, cells were treated with either 10 μM N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal
(MG132, Tocris) for 4 h, 1 μM thapsigargin (Sigma) for 60 min, 0.5 mM sodium arsenite
(Sigma) for 30 min, 1 mM hydrogen peroxide for 60 min or 0.4 M D-sorbitol (Sigma) for
60 min. Cells were transiently transfected using Fugene HD (Promega), with a Fugene:DNA
ratio of 3:1, for 24 hours. Plasmids harboring N-terminally myc-tagged wild-type or mutant
human TDP-43 sequences (TARDBP, wild-type reference sequence NM_007375.3) were pur-
chased from Origene. The presence of the A90V (c.269C>T) and M337V (c.1009A>G) muta-
tions was confirmed by DNA sequencing performed by GENEWIZ (forward sequencing
primer 5'-GGACTTTCCAAAATGTCG-3'; reverse sequencing primer 5’-ATTAGGA
CAAGGCTGGTGGG-3’). NLS-EGFP was a gift from Rob Parton (Addgene plasmid # 67652)
[39].
In a subset of D-sorbitol stress experiments, HeLa cells were pre-treated with 50 μM of the
irreversible pan-caspase inhibitor Z-Val-Ala-Asp-(OMe)-Fluoromethyl Ketone (Z-VAD-
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(OMe)-FMK, Cayman Chemical) or DMSO solvent control. After 30 min of caspase inhibi-
tion, 0.4 M of D-sorbitol or an equivalent volume of fresh medium was added and cells were
incubated for a further 60 min before processing for immunofluorescence staining or fraction-
ation of cells into enriched nuclear and cytosolic fractions.
To assess the rescue of TDP-43 and HuR cellular localization, cells were treated with 0.4 M
D-sorbitol for 1 h and then allowed to recover in normal medium for 0 min, 15 min or 60 min.
Protein biochemistry and Western blot analysis
For analysis of total protein, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer
(50 mM Tris HCl, 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate [SDS]; Boston Bioproducts) supplemented with protease inhibitors
(Complete, Roche), phosphatase inhibitors (PhosSTOP, Roche) and 2 mM ethylenediamine-
tetraacetic acid (EDTA). Cellular debris was removed by centrifugation at 16’000 x g for 15
min. Protein concentrations were determined using the bicinchoninic acid (BCA) assay
(Thermo Fisher Scientific). Cellular fractionation experiments to obtain enriched cytosolic
and nuclear fractions from cells grown on 60 mm dishes (Costar) were performed using a cell
fractionation kit (Cell Signaling Technology) according to the manufacturer’s standard proto-
col. RIPA-soluble and–insoluble protein fractions were extracted according to a protocol
adapted from Cohen et al. [40]. Briefly, following lysis of cells grown in a 6-well plate using
Fig 1. TDP-43 domain structure with caspase and calpain cleavage sites. (A) Schematic of the full-
length, 414 amino acid long TDP-43 protein. NLS = nuclear localization signal, RRM1/RRM2 = RNA
recognition motifs, NES = nuclear export signal. The A90V variant and the M337V mutation are indicated in
red. CS = (putative) caspase cleavage site, CL = (putative) calpain cleavage site. (B) Table of TDP-43
caspase and calpain cleavage sites described in the literature.
https://doi.org/10.1371/journal.pone.0177181.g001
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300 μl RIPA buffer supplemented with protease inhibitors (Complete, Roche) and 2 mM
EDTA, lysates were sonicated twice for 15 seconds using a Soniprep 150 (MSE). Samples were
then centrifuged at 100,000 x g and 4˚C for 30 min in 1.5 ml microfuge tubes using an Optima
TLX ultracentrifuge with a TLA100.4 rotor fitted with Delrin adaptors (all Beckman). The
supernatant was collected as the RIPA-soluble fraction and the pellets were washed with 300 μl
RIPA buffer and centrifuged at 100,000 x g and 4˚C for 30 min. Pellets were extracted with
100 μl urea buffer (7 M urea, 2 M thiourea, 30 mM Tris pH 8.5, 4% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS)) and sonicated twice for 15 sec. Samples
were centrifuged at 100,000 x g for 30 min at room temperature and the supernatant was col-
lected as the RIPA-insoluble, urea-soluble fraction. For Western blots, both RIPA and urea
fractions were diluted 1:1 with RIPA buffer.
Protein lysates and fractionated samples were separated on Tris-glycine SDS polyacryl-
amide gels (polyacrylamide concentrations ranging from 10–15%) and transferred onto poly-
vinylidene difluoride (PVDF, Millipore) membranes. Blocking solution and antibody dilutions
were made up in 5% skimmed milk in Tris-buffered saline and 0.1% Tween-20 (TBS-T). West-
ern blots were developed with enhanced chemiluminescent substrates (Clarity, BioRad; Visiglo
HRP, Amresco). Digital images were acquired with a Chemidoc MP imaging system (BioRad).
Where required, blots were stripped with stripping buffer for 15 min at room temperature
(Thermo Fisher Scientific), blocked in 5% milk in TBS-T and reprobed with appropriate load-
ing control antibodies.
Immunofluorescence staining
Following stress treatments, cells were washed with phosphate-buffered saline (PBS) and fixed
for 15 min with 4% paraformaldehyde (in PBS) before solubilization with 0.25% Triton-X (in
PBS) for 10 min. Cells were washed again and blocked for 1 hour in 10% normal goat serum
in PBS (Abcam). The fixed cells were incubated in primary antibody overnight at 4˚C in a
humidified chamber, and in secondary antibody for 1 hour at room temperature. Coverslips
were mounted on microscope slides with Prolong Gold antifade with DAPI (Thermo Fisher
Scientific) or counterstained with Hoechst 33342 (2 μg/ml; Thermo Fisher Scientific) and
mounted with Prolong Gold antifade (Thermo Fisher Scientific). Cells transfected with
NLS-EGFP were counterstained with Hoechst and mounted with Prolong Gold antifade.
Images were acquired using a Nikon A1 confocal/Eclipse Ti inverted microscope system and
NIS Elements software (Nikon).
Antibodies
We used the following antibodies for detection of proteins by Western blot: rabbit carboxy-
and amino-terminal TDP-43 (1:1,000–1:2,500; 12892-1-AP, 1:5,000; 10782-2-AP, Proteintech),
mouse α-tubulin (1:15,000; ab80779, Abcam), mouse GAPDH (1:3,000; sc-32233, Santa
Cruz), rabbit GAPDH (1:2,000; sc-25778, Santa Cruz), rabbit Lamin B1 (1:5,000; ab133741,
Abcam), mouse histone H3 (1:6,000; 96C10, 3638, Cell Signaling Technology), rabbit caspase-
3 (1:1,000; 8G10, 9665, Cell Signaling Technology), mouse caspase-9 (1:500; MAB8301, R&D
Systems), mouse Nup153 QE5 (1:750; 906201, Biolegend). Anti-mouse and anti-rabbit horse-
radish peroxidase-coupled secondary antibodies were obtained from Jackson Immunoresearch
(1:7,000). For immunofluorescence staining, we used rabbit carboxy- and amino-terminal
TDP-43 (1:150 and 1:500), mouse myc 9E10 (1:200; sc-40, Santa Cruz) and mouse HuR (1:300;
sc-5621, Santa Cruz). Secondary anti-mouse and anti-rabbit Alexa-488-, Alexa-555- and
Alexa-568-coupled antibodies were purchased from Thermo Fisher Scientific.
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Quantification of immunofluorescence images and Western blots and
statistical analysis
Western blot band densities were quantified with Image Lab 5 (BioRad). For immunofluores-
cence signal quantification of the cytosolic and nuclear TDP-43 ratios we used the Fiji open
source program [41]. For statistical analysis, we used GraphPad Prism 6. For statistical analy-
sis, we used either two-tailed Student’s t test or one-way ANOVA followed by Dunnett’s or
Tukey’s multiple comparisons analysis as indicated for each experiment.
Results
Sorbitol triggers the formation of a 35 kDa truncated form of TDP-43 that
is localized in the cytosol
First, we sought to identify a compound capable of inducing TDP-43 cleavage in a cellular sys-
tem. To this end, we treated HeLa cells with various compounds described in the literature
that were shown to induce pathological changes in TDP-43, though not necessarily TDP-43
truncation. We tested the proteasome inhibitor MG132 (10 μM, 4 h) [13, 42], the oxidative
stressors hydrogen peroxide (1 mM, 60 min) [43] and sodium arsenite (0.5 mM, 30 min) [44],
the sarco-endoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin (1 μM, 60 min) [15, 29]
and the oxidative and osmotic stressor D-sorbitol (0.4 M, 60 min) [14]. However, while
MG132 as well as thapsigargin and D-sorbitol have been described to promote cleavage of
TDP-43, we observed a reduction of full-length TDP-43 as well as the formation of a 35 kDa
fragment (CTF35) with D-sorbitol only (Fig 2) [14, 29, 42]. We also detected HuR- and TDP-
43-positive stress granules in a small number of sorbitol-treated cells (control: 0.57 ± 0.57% of
cells; sorbitol: 11.4 ± 2.3% of cells, p = 0.017) (one-way ANOVA: F2,6 = 13.16, P = 0.0064, fol-
lowed by Tukey’s multiple comparisons test) (S1 Fig). These findings are in line with Dewey
et al., who showed that treatment of HEK293T cells with D-sorbitol leads to the association of
TDP-43 with stress granules as well as to the formation of a 35 kDa cleavage product of TDP-
43 [14]. In addition, we fractionated cell lysates of untreated or sorbitol-stressed HeLa cells
into RIPA-soluble and RIPA-insoluble/urea-soluble proteins (S2 Fig). However, we did not
find any evidence that sorbitol induces the aggregation of endogenous full-length TDP-43 or
CTF35 into insoluble protein inclusions.
We quantified both full-length TDP-43 and CTF35 in untreated, sorbitol- and hydrogen
peroxide-treated HeLa cells and found that sorbitol led to a significant reduction in full-length
TDP-43 (0.61 ± 0.08-fold decrease compared to control, p = 0.0003) (one-way ANOVA: F2,9 =
19.87, P = 0.0005, followed by Dunnett’s multiple comparisons test) and an increase in the 35
kDa cleavage product (34.1 ± 10.0-fold increase compared to control, p = 0.0044) (Fig 3A–3C).
We observed no significant increase in the 35 kDa fragment after treatment with 1 mM hydro-
gen peroxide (0.67 ± 0.66-fold increase, p = 0.995) (one-way ANOVA: F2,9 = 11.41, P = 0.0034,
followed by Dunnett’s multiple comparisons test).
By fractionating untreated and stressed HeLa cells into cytoplasmic and nuclear compo-
nents, we detected CTF35 by Western blot in the cytoplasmic fraction in sorbitol-treated
samples, while full-length TDP-43 in the nuclear fraction was reduced (Fig 3D, Fig 4C). Immu-
nofluorescence staining of sorbitol-treated HeLa cells indicated that TDP-43 accumulated in
the cytoplasm compared to control cells (control cells: 7.4 ± 1.7% of total TDP-43 signal; sorbi-
tol-treated cells: 32.4 ± 4.5% of total TDP-43 signal; p = 0.0021, Student’s t test) (Fig 3E and
3F). While the antibody used for staining is unable to distinguish between full-length TDP-43
and the 35 kDa cleavage product, this result nevertheless supports the finding of a nuclear to
cytoplasmic relocalization phenotype.
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Caspase inhibition blocks the sorbitol-induced formation of CTF35, but
does not prevent the translocation of full-length TDP-43 to the cytoplasm
In addition to TDP-43 cleavage, Dewey et al. also observed poly ADP ribose polymerase
(PARP) cleavage in HEK293T cells treated with sorbitol, suggesting that these cells are under-
going apoptosis and thus caspase-3 is activated, which might in turn be responsible for the for-
mation of the 35 kDa fragment of TDP-43 [14]. We wanted to confirm that the formation of
CTF35 we detected in sorbitol-stressed HeLa cells was caused by activation of caspases. To this
end, we pre-treated HeLa cells for 30 min with 50 μM of the irreversible pan-caspase inhibitor
Z-VAD-(OMe)-FMK or DMSO control prior to adding 0.4 M sorbitol for one hour (Fig 4A
and 4B). We found that pre-treatment of cells with the caspase inhibitor indeed abrogated
the sorbitol-induced cleavage of TDP-43 and formation of CTF35 (Δ[sorb–Z-VAD/sorb] =
17.3 ± 3.3, p = 0.0001) (one-way ANOVA: F3,16 = 26.95, P< 0.0001, followed by Tukey’s multi-
ple comparisons test), indicating that sorbitol induces the activation of caspases, which in turn
cleave full-length TDP-43. Using a caspase-3-specific antibody, we confirmed that caspase-3 is
activated by sorbitol, and that pre-treatment with ZVAD-FMK inhibits its activation (Fig 5A).
Z-VAD-FMK also completely abrogated the cleavage of lamin B1, a known substrate of acti-
vated caspase-3 (Fig 5A) [45]. Furthermore, we showed that sorbitol-induced, caspase-medi-
ated truncation of TDP-43 is a cell-type-dependent process, as treatment of SH-SY5Y cells
with 0.4 M D-sorbitol for 1 hour neither led to activation of caspase-3 nor to the generation of
Fig 2. The osmotic and oxidative stressor D-sorbitol triggers cleavage of endogenous TDP-43 in HeLa
cells. Untransfected HeLa cells expressing endogenous TDP-43 were treated with 10 μM MG132 for 4 h, 1
mM hydrogen peroxide (H2O2) for 1 h, 0.5 mM sodium arsenite (SA) for 30 min, 1 μM thapsigargin (TH) for 1
h, 0.4 M D-sorbitol (Sorb) for 1 h or with respective H2O and DMSO solvent controls. Western blot detection
using a polyclonal TDP-43 antibody revealed a truncated product of TDP-43 with an approximate molecular
weight of 35 kDa (CTF35, indicated by arrowhead) after treatment with D-sorbitol, but not with the other
stressors.
https://doi.org/10.1371/journal.pone.0177181.g002
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CTF35 despite fulminant stress granule formation, indicating a functioning stress response (S3
Fig).
We then performed immunofluorescence staining of HeLa cells treated with sorbitol in the
presence or absence of ZVAD-(OMe)-FMK in order to determine whether caspase inhibition
can also rescue the TDP-43 relocalization from the nucleus to the cytoplasm (Fig 4C and 4D).
However, we found no significant difference in cytoplasmic TDP-43 accumulation after sorbi-
tol stress between untreated cells and cells treated with ZVAD-(OMe)-FMK in immunofluo-
rescence staining with a carboxy-terminal TDP-43 antibody (cytoplasmic TDP-43: 42.5 ± 3.7%
Fig 3. D-sorbitol induces the formation of a 35 kDa cleavage product of TDP-43 that is localized in the
cytosol. (A) Western blot of TDP-43 protein (C-terminal antibody) after treatment of HeLa cells with 0.4 M D-
sorbitol or 1 mM hydrogen peroxide for one hour. (B), (C) Densitometry analysis of (B) full-length TDP-43, (C)
35 kDa fragment of TDP-43 (CTF35). Densitometry results represent mean signal ± SEM (N = 4). (D)
Detection of CTF35 in cytoplasmic (Cyto) and nuclear (Nuc) fractions of HeLa cells after treatment with D-
sorbitol or hydrogen peroxide. (E) Immunofluorescence detection of cytoplasmic TDP-43 after D-sorbitol
treatment. Scale bar = 15 μm. (F) Quantification of cytoplasmic TDP-43 immunofluorescence signal. Results
represent mean TDP-43 immunofluorescence signal in the cytoplasm as a percentage of total TDP-43 signal
in the cell ± SEM (N = 4). ** p < 0.01, *** p < 0.001.
https://doi.org/10.1371/journal.pone.0177181.g003
Sorbitol-induced cleavage of TDP-43
PLOS ONE | https://doi.org/10.1371/journal.pone.0177181 May 16, 2017 7 / 20
in cells treated with sorbitol, 38.5 ± 6.3% in cells treated with ZVAD + sorbitol; p = 0.864 (one-
way ANOVA: F3,8 = 32.34, P< 0.0001, followed by Tukey’s multiple comparisons test) (Fig
4D). In order to confirm this result and to determine whether the cytoplasmic TDP-43 in sam-
ples treated with both caspase inhibitor and D-sorbitol was indeed full-length TDP-43, we
fractionated untreated and treated cell samples into nuclear and cytoplasmic fractions and
Fig 4. Inhibition of caspases prevents the formation of CTF35 of TDP-43, but does not prevent relocalization
of the full-length protein to the cytosol. (A) TDP-43 Western blot of samples treated with or without D-sorbitol
after pre-treatment with caspase inhibitor Z-VAD-FMK or DMSO control. α-tubulin was used as a loading control.
FL = full-length TDP-43, CTF35 = 35 kDa C-terminal fragment of TDP-43. (B) Densitometry quantification of the 35
kDa fragment of TDP-43 after sorbitol stress in the absence or presence of caspase inhibitor (N = 5). (C) Immuno-
fluorescence staining of nuclear and cytoplasmic TDP-43 using a C-terminal TDP-43 antibody. Cells were treated
with or without D-sorbitol after pre-treatment with caspase inhibitor. Scale bar = 15 μm. (D) Quantification of nuclear
and cytoplasmic TDP-43 fluorescence signals (N = 3). (E) Western blot of nuclear and cytoplasmic fractions of
stressed HeLa cells. GAPDH was used as a control for the cytoplasmic fractions, histone H3 was chosen to confirm
enrichment of the nuclear fraction. All results represent mean ±SEM; ** p < 0.01, *** p < 0.001.
https://doi.org/10.1371/journal.pone.0177181.g004
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resolved them by SDS-PAGE (Fig 4E). While we found, as expected, that pre-treatment with
Z-VAD-FMK abrogated the sorbitol-induced formation and cytoplasmic accumulation of
CTF35, we detected an accumulation of full-length, uncleaved TDP-43 protein in the cyto-
plasmic fraction, suggesting that TDP-43 cleavage is not a prerequisite for trapping the protein
in the cytoplasm. Caspase inhibition also did not rescue the formation of TDP-43- and HuR-
positive stress granules in response to sorbitol (sorbitol: 11.4 ± 2.3% of cells; Z-VAD + sorbitol:
13.6 ± 2.3% of cells, p = 0.71) (one-way ANOVA: F2,6 = 13.16, P = 0.0064, followed by Tukey’s
multiple comparisons test) (S1 Fig).
Sorbitol-induced cytoplasmic relocalization is a reversible phenomenon
not limited to TDP-43
The nuclear envelope is the cellular barrier that demarcates the nucleus. During apoptosis,
nuclear permeability increases due to the breakdown of the nuclear pore complex (NPC),
which regulates traffic of large macromolecules between the cytosol and nucleus [46–48]. As a
result, proteins found in the nucleus disperse throughout the cytoplasm, while cytoplasmic
proteins enter the nucleus. Nup153, a component of the NPC thought to be crucially involved
Fig 5. Sorbitol-dependent TDP-43 relocalization is reversible and not dependent on Nup153 cleavage. (A)
Western blot of nuclear pore complex protein Nup153, nuclear lamina component lamin B1, procaspases -3 and -9 and
their activated forms caspase-3 and caspase-9 in HeLa cells treated with sorbitol after pre-treatment with DMSO
control or caspase inhibitor Z-VAD-FMK. α-tubulin was used as a loading control. (B) Immunofluorescence staining of
nuclear-cytoplasmic shuttling proteins TDP-43 (green) and HuR (red) in sorbitol-stressed HeLa cells after 0 min, 15 min
or 60 min rescue in normal medium. Scale bar = 30 μm. (C) Quantification of cytoplasmic TDP-43 and HuR protein in
sorbitol-treated HeLa cells after 0 min, 15 min or 60 min rescue (N = 3). Results represent mean percentage of
cytoplasmic signal ± SEM;** p < 0.01, *** p < 0.001, **** p < 0.0001.
https://doi.org/10.1371/journal.pone.0177181.g005
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in modulating nuclear permeability, has been shown to be cleaved by caspases [49, 50]. We
found that sorbitol indeed initiates cleavage of Nup153; however, the majority of Nup153
remained uncleaved after one hour of sorbitol treatment (Fig 5A). Furthermore, pre-treatment
of HeLa cells with the caspase inhibitor Z-VAD-FMK abrogated the cleavage of Nup153. We
thus conclude that the cytoplasmic relocalization of TDP-43 as a response to sorbitol stress is
not the result of degradation of Nup153, as TDP-43 accumulates in the cytoplasm in HeLa cells
pre-treated with caspase inhibitor prior to the sorbitol insult. We also investigated the activity
of caspase-9, an initiator caspase that modulates nuclear leakiness by affecting hydrophobic
proteins which form a permeability barrier in the NPC through hydrophobic protein-protein
interactions [46, 51]. We detected cleaved caspase-9, an indicator of autocatalytic activity, in
HeLa cells treated with sorbitol (Fig 5A). While pre-treatment with the pan-caspase inhibitor
Z-VAD-FMK partially suppressed caspase-9 autocatalytic cleavage, we still observed some cas-
pase-9 activity. As activation of caspase-9 has been shown to be required for the release of GFP
fused to a nuclear localization signal (NLS-GFP) [46], we sought to determine whether sorbitol
affects the localization of this fusion protein. To this end, we treated HeLa cells transfected with
NLS-EGFP with sorbitol for one hour. In control cells, we detected NLS-EGFP predominantly
in the nuclear compartment, while in sorbitol-treated cells, the percentage of nuclear GFP signal
was significantly lower (control: 73.2 ± 1.5% of total EGFP signal; sorbitol: 62.8 ± 3.3% of total
EGFP signal, p = 0.041) (S4 Fig). Pre-treatment with Z-VAD-FMK did not rescue the relocaliza-
tion of NLS-EGFP (Z-VAD + sorbitol: 58.1 ± 3.2% of total EGFP signal, p = 0.010) (one-way
ANOVA: F2,8 = 7.754, P = 0.0134, followed by Dunnett’s multiple comparisons test).
Finally, we performed a rescue experiment to determine whether the changes in nuclear
permeability and TDP-43 mislocalization caused by the sorbitol insult were reversible. Fol-
lowing a one hour exposure to 0.4 M D-sorbitol, cells were left to recover in fresh normal
medium for 0 min, 15 min or 60 min (Fig 5B and 5C). In recovering cells, TDP-43 in the cyto-
plasm (as a percentage of total TDP-43 signal) gradually decreased, with cytoplasmic TDP-43
35.6 ± 0.8%, 25.6 ± 1.0% and 11.6 ± 1.4% of total TDP-43 after 0 min, 15 min and 60 min of
recovery, respectively (one-way ANOVA: F2,6 = 119.7, P< 0.0001, followed by Dunnett’s mul-
tiple comparisons test: 0 vs. 15 min p = 0.001, 0 vs. 60 min p = 0.001). This decrease in the cyto-
plasmic-to-nuclear TDP-43 ratio was paralleled by an increase in nuclear TDP-43 signal (S5A
Fig). This result indicates that the nuclear changes leading to the mislocalization of TDP-43 in
response to sorbitol stress are transient and reversible. We also investigated the rescue of HuR
localization, another nuclear-cytoplasmic shuttling, RNA-binding protein (Fig 5B and 5C).
While the cytoplasmic-to-nuclear HuR signal ratio (0 min: 50.6 ± 3.1%; 60 min: 21.0 ± 4.9%)
as well as total nuclear HuR significantly recovered after a 60 minute rescue period, we ob-
served no improvement after 15 min (0 min: 50.6 ± 3.1%; 15 min: 50.6 ± 3.1%) (one-way
ANOVA: F2,6 = 18.65, P = 0.0027, followed by Dunnett’s multiple comparisons test: 0 vs. 15
min p = 0.96, 0 vs. 60 min p = 0.0037) (Fig 5C, S5B Fig). Furthermore, while the nuclear-cyto-
plasmic distribution of TDP-43 appeared homogenous between cells after 15 and 60 min of
recovery, we observed heterogeneous cell populations in the HuR staining, with some cells
showing a clear nuclear localization of HuR, while others–despite nuclear TDP-43 localiza-
tion–displayed an even distribution of HuR throughout the cell.
The A90V variant of TDP-43 confers resistance against caspase-
induced cleavage
The caspase cleavage site resulting in the formation of the TDP-43 cleavage product CTF35
lies after aspartic acid 89 (Fig 1). Introduction of an aspartic acid to glutamic acid mutation at
this amino acid (D89E) confers resistance against caspase-mediated cleavage [27, 29, 32]. This
Sorbitol-induced cleavage of TDP-43
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mutation has not been described in any ALS or FTD patients, and has only been used as a
proof of concept to confirm the actual caspase cleavage site. However, an alanine to valine
amino acid substitution at residue 90 (A90V) has been described in an FTLD/ALS patient with
a family history of dementia [52]. Using D-sorbitol as an inducer of caspase activity, we sought
to determine whether the A90V mutation, which lies directly next to the carboxy-side of the
second aspartic acid of the caspase-3 recognition motif within the NLS, has an effect on TDP-
43 cleavage propensity at that site (Fig 6A and 6B). After 24 h of transfection, we detected low
levels of CTF35 in HeLa cells even in the absence of sorbitol stress (Fig 6A). Following expo-
sure of transfected cells with D-sorbitol, we saw an increase in the cleaved fragment. Interest-
ingly, less CTF35 was detected in A90V-transfected cells compared to WT and M337V mutant
TDP-43 both in untreated (Δ[WT-A90V]: 0.748 ± 0.090, p = 0.0224; Δ[M337V-A90V]:
0.573 ± 0.277, p = 0.074) (one-way ANOVA: F2,9 = 5.989, P = 0.022, followed by Tukey’s multi-
ple comparisons test) and sorbitol-treated cells (Δ[WT-A90V]: 0.868 ± 0.049, p = 0.0001; Δ
[M337V-A90V]: 0.708 ± 0.148, p = 0.0006) (one-way ANOVA: F2,9 = 29.3, P = 0.0001, fol-
lowed by Tukey’s multiple comparisons test) (Fig 6B). Furthermore, there was significantly
more full-length TDP-43 present in A90V-transfected cells compared to WT and M337V-
transfected cells following D-sorbitol treatment (Δ[WT-A90V]: 0.058 ± 0.021, p = 0.032; Δ
[M337V-A90V]: 0.080 ± 0.021, p = 0.005), suggesting that full-length TDP-43 is partially res-
cued from cleavage or degradation (one-way ANOVA: F2,9 = 9.77, P = 0.0056, followed by
Tukey’s multiple comparisons test) (Fig 6C). As we detected robust activation of caspase-3 fol-
lowing treatment with D-sorbitol regardless of the expressed TDP-43 construct, the lower lev-
els of CTF35 in A90V-expressing cells were not due to a lack of caspase activity (Fig 6A). We
thus conclude that the alanine to valine amino acid substitution at residue 90 confers a resis-
tance against caspase-mediated cleavage at that site.
We also investigated the subcellular localization of WT and mutant TDP-43 in HeLa cells
(Fig 6D–6F). We found a significant increase in cells with cytoplasmic TDP-43 in M337V
mutant cells compared to WT-expressing cells (WT: 36.8 ± 1.6%, M337V: 49.2 ± 3.7% of
transfected cells; p = 0.021) (Fig 6D and 6E). Similarly, we found a trend towards an increase
in the number of A90V-expressing cells with cytoplasmic TDP-43 compared to WT (A90V:
45.9 ± 3.0% of transfected cells, p = 0.089) (one-way ANOVA: F2,12 = 4.758, P = 0.03, followed
by Dunnett’s multiple comparisons test). These results are in line with published literature
showing cytoplasmic accumulation of TDP-43 in A90V- and M337V-expressing cells in vitro
[52, 53]. In contrast, we did not find a significant difference in the proportion of WT-, A90V-
or M337V-transfected cells with cytoplasmic TDP-43 after a one hour treatment with sorbitol
(WT: 50.5 ± 7.2%, A90V: 53.1 ± 6.1%, M337V: 44.2 ± 2.8% of transfected cells) (one-way
ANOVA followed by Dunnett’s multiple comparisons test, F2,12 = 0.664, P = 0.533) (Fig 6E
and 6F). However, in sorbitol-treated cells the overexpressed myc-TDP-43 displayed a granu-
lar staining pattern, which could suggest the formation of insoluble, aggregated TDP-43 (S6
Fig). To confirm this, we fractionated lysates of control and sorbitol-treated HeLa cells into
RIPA-soluble and RIPA-insoluble, urea-soluble material (Fig 6G and 6H). We detected both
full-length TDP-43 and CTF35 in the urea fraction in untreated HeLa cells. We only observed
very low levels of CTF35 in the RIPA-soluble fraction. When we quantified TDP-43 in the
urea fraction (full-length + CTF35, normalized to TDP-43 in the RIPA-soluble fraction) in
untreated cells, we found significantly more TDP-43 in M337V-mutant expressing cells com-
pared to WT (Δ = 76.5 ± 30.3%, p = 0.0334) (Fig 6H). There was no significant increase in
insoluble TDP-43 in A90V-expressing cells (Δ = 16.8 ± 18.4%, p = 0.787) (one-way ANOVA:
F2,15 = 3.873, P = 0.0441, followed by Dunnett’s multiple comparisons test). Sorbitol treatment
caused a decrease in RIPA-soluble TDP-43 and an increase in TDP-43 in the urea fraction,
confirming that sorbitol promotes the aggregation of overexpressed TDP-43 regardless of
Sorbitol-induced cleavage of TDP-43
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Fig 6. The A90V mutation confers resistance against caspase-mediated cleavage of TDP-43 within the nuclear localization
sequence. (A) Western blot detection of full-length and 35 kDa fragment of TDP-43 as well as cleaved caspase-3 in HeLa cells
transfected with WT, A90V or M337V mutant TDP-43 and treated with 0.4 M D-sorbitol for 1 hour. ovx = overexpressed WT, A90V or
M337V TDP-43, endo = endogenous TDP-43. α-tubulin was used as a loading control. (B), (C) Western blot quantification of (B)
cleaved 35 kDa TDP-43 normalized to full-length TDP-43, (C) full-length TDP-43 in untreated HeLa cells and cells after treatment
with D-sorbitol. Result represents mean signal ± SEM (N = 4). (D) Immunofluorescence staining of control or sorbitol-stressed HeLa
cells transfected with WT, A90V or M337V TDP-43 and probed with anti-myc (green) and anti-TDP-43 (red) antibodies. Cells with
Sorbitol-induced cleavage of TDP-43
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mutation. Last, we investigated stress granule formation in HeLa cells overexpressing TDP-43.
We detected TDP-43-positive stress granules in a very small number of untreated cells (<4%
of transfected cells). Sorbitol treatment caused an increase in the number of cells with stress
granules (>8% of transfected cells). However, we found no difference in the number of cells
with TDP-43-positive stress granules between genotypes under either control or stress condi-
tions (S7 Fig). However, this finding does not exclude the possibility that the A90V and/or
M337V mutations have more subtle effects on stress granule composition or dynamics.
Discussion
While the occurrence of C-terminal fragments of TDP-43 is a common pathological hallmark
in ALS and FTD pathology, the significance of TDP-43 truncation for disease pathogenesis
remains unclear. It is unknown whether TDP-43 fragments are disease-relevant species or a
by-product of the cellular protein degradation machineries’ attempt to get rid of toxic full-
length TDP-43 species. For example, whether C-terminal fragments affect cell viability is
uncertain, with various papers suggesting reduced [29], similar [22] or increased [31] toxicity
compared to full-length TDP-43 depending on the fragment used and expression system cho-
sen. On the other hand, the current literature suggests that TDP-43 CTFs are prone to aggrega-
tion and hyperphosphorylation, and as they lack a nuclear localization sequence, accumulate
in the cytoplasm [22, 28, 54, 55]. These features are defining hallmarks of TDP-43
proteinopathies.
In the current study, we have adapted a protocol by Dewey et al. that describes the use of
high concentrations of D-sorbitol, a sugar alcohol, as an osmotic and oxidative stressor in
HEK293T cells that drives TDP-43 cleavage, resulting in the generation of a 35 kDa fragment
[14]. D-sorbitol use as a stressor to elicit TDP-43 cleavage is fast-acting, with the formation of
the CTF35 TDP-43 fragment occurring within one hour of treatment in HeLa cells in our
experiments. In a first effort, we sought to confirm whether the sorbitol-induced cleavage of
TDP-43 and the formation of the CTF35 fragment are indeed mediated by the activation of
caspases. Dewey et al. showed that cleavage of Poly(ADP-ribose) polymerase (PARP), a known
substrate of caspase-3, preceded cleavage of TDP-43 in sorbitol-treated HEK293T cells [14].
However, this finding is not a direct proof, as caspase-independent PARP cleavage has previ-
ously been described [56, 57]. By pre-treating HeLa cells with the pan-caspase inhibitor
Z-VAD-FMK prior to sorbitol stress, we abrogated TDP-43 cleavage, confirming that the for-
mation of the 35 kDa TDP-43 fragment CTF35 in response to sorbitol stress is indeed caspase-
dependent, as suggested by Dewey et al.. This is in line with the literature showing that CTF35
is formed in response to caspase activation [29, 32].
By fractionating cells into nuclear and cytoplasmic fractions, we showed that CTF35 accu-
mulates in the cytoplasm of sorbitol-treated HeLa cells, while full-length protein in the nucleus
is depleted. However, while pre-treatment of cells with caspase inhibitor prevented the cleav-
age of TDP-43, we found that it did not rescue the relocalization of full-length TDP-43 from
the nucleus to the cytoplasm. This result suggests that C-terminal protein truncation is not
necessary to trap TDP-43 in the cytoplasm and that the cytoplasmic relocalization of TDP-43
likely precedes its caspase-dependent cleavage. We also found that HuR, another nuclear-
cytoplasmic TDP-43 are indicated by arrowhead. Scale bar = 50 μm. (E), (F) Quantification of transfected cells with cytoplasmic
TDP-43 under control (E) or sorbitol (F) conditions. Result represents mean percentage of transfected cells with cytoplasmic TDP-
43 ± SEM (N = 5). (G) Western blot detection of RIPA-soluble and urea-soluble TDP-43 WT, A90V or M337V in untreated and
sorbitol-treated HeLa cells. GAPDH was used as a fractionation control. (H) Quantification of total TDP-43 (full-length + CTF35) in
RIPA fraction normalized to TDP-43 in urea fraction in untreated cells. Results represent mean normalized urea/RIPA ratio ± SEM
(N = 6). * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA followed by Tukey’s or Dunnett’s multiple comparisons test.
https://doi.org/10.1371/journal.pone.0177181.g006
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cytoplasmic shuttling protein, relocalizes to the cytoplasm in response to sorbitol, as does
NLS-EGFP, albeit with a smaller effect size than seen with TDP-43 and HuR. The accumula-
tion of TDP-43 in the cytoplasm is thus likely the result of sorbitol-induced leakiness of the
nuclear envelope. One of the factors known to regulate nuclear permeability is the nuclear
pore complex component Nup153, which is degraded in apoptotic cells [46, 48, 49]. We only
found a small fraction of Nup153 cleaved in response to sorbitol, and cleavage was completely
suppressed by caspase inhibition, indicating that the degradation of this NPC protein is not
responsible for the observed nuclear leakiness. Furthermore, Z-VAD-FMK did not completely
inhibit the autocatalytic cleavage of caspase-9, an initiator caspase that regulates nuclear trans-
port and increases nuclear leakiness by perturbing the permeability barrier inside the NPC
[46, 51]. The possibility that sorbitol-induced redistribution of TDP-43 is dependent on cas-
pase-9 is in line with a study showing that the expression of a dominant-negative form of cas-
pase-9 prevents nuclear leakiness and the collapse of the Ran gradient required for nuclear
import [46]. Furthermore, several studies have shown that oxidative and osmotic stressors can
trigger the collapse of the Ran gradient [58, 59]. Interestingly, elevated serum levels of caspase-
9 as well as activated caspase-9 in spinal cord have been described in ALS patients [60, 61]. We
also demonstrated that the sorbitol-induced changes in nuclear permeability are transient, as
TDP-43 and–with a lag time–HuR relocalized to the nucleus after a recovery period. In con-
clusion, we have demonstrated that the sorbitol-induced, reversible redistribution of TDP-43
is the result of either caspase-independent or caspase-9-dependent changes in nuclear per-
meability and/or nuclear transport machinery that precede the breakdown of the nuclear
envelope.
We also used sorbitol to investigate the cleavage propensity and cytoplasmic accumulation
of the A90V variant of TDP-43. This variant lies within the bipartite nuclear localization
sequence of TDP-43 directly adjacent to the caspase-3 cleavage site after Asp89. Genetic stud-
ies have detected the A90V variant both in ALS cases as well as in healthy control individuals,
leaving the impact of this single amino acid mutation on disease pathogenesis unclear [52, 62–
64]. A recent in vitro study has shown that A90V-TDP-43 protein incubated with purified
caspase-3 is less efficiently cleaved than WT-TDP-43 [65]. We addressed the question of the
impact of the A90V sequence variant on TDP-43 cleavage using a cellular system, by transfect-
ing HeLa cells with WT, A90V or M337V TDP-43 before treatment with D-sorbitol. We
found that even in the absence of sorbitol, CTF35 is formed and found predominantly aggre-
gated, and that it accumulates further after sorbitol stress. Both with and without sorbitol treat-
ment, the A90V variant was less efficiently cleaved at the Asp89 residue than WT or M337V
TDP-43. Interestingly, recent studies have shown that the cleavage-resistant D89E TDP-43
mutant confers no toxicity in a cellular expression system, while the disease-related D169G
mutation, which is more efficiently cleaved at Asp89 than WT TDP-43, is highly toxic [27, 65].
This suggests that CTF35 might be an important mediator of cellular toxicity. On the other
hand, we found a trend towards increased cytoplasmic TDP-43 in the A90V mutant in line
with published literature [52, 66]. This apparent dichotomy between increased cytoplasmic
accumulation and decreased generation of toxic fragments could explain why this variant is
found both in patients and healthy controls, as the balance between increased toxicity due to
TDP-43 mislocalization and reduced toxicity due to reduced formation of C-terminal frag-
ments might be tipped in each direction depending on the carriers’ specific genetic makeup
and environmental exposure to additional risk factors.
In summary, we have described here the use of D-sorbitol as an inducer of caspase-depen-
dent cleavage of TDP-43 to investigate the relationship between TDP-43 cleavage and cyto-
plasmic relocalization. We also looked at the impact of these phenotypes in the context of the
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TDP-43 mutants A90V and M337V and observed cleavage resistance of the A90V variant in a
cellular context.
At the time this study was conducted, the cleavage resistance of the A90V variant at the
Asp89 cleavage site was not published. However, a recent paper published by Chiang et al.
demonstrated this resistance against caspase-3-mediated cleavage in vitro [65].
Supporting information
S1 Fig. Sorbitol induces the formation of stress granules in HeLa cells. HeLa cells were
either pre-treated with pan-caspase inhibitor Z-VAD-FMK or DMSO control before 0.4 M
D-sorbitol was added as a stressor for 1 h. Control cells were not treated with either sorbitol
or Z-VAD-FMK. (A) Example of immunofluorescence staining of untreated and sorbitol-
stressed HeLa cells. Stress granules (indicated by arrowhead) are defined as cytoplasmic puncta
co-stained with TDP-43 (green) and the stress granule marker HuR (red). Scale bar = 30 μM.
(B) Quantification of cells with a minimum of three TDP-43+/HuR+ stress granules (N = 4).
Results represent mean number of cells with stress granules ± S.E.M.;  p< 0.05,  p< 0.01;
one-way ANOVA (F2,6 = 13.16, P = 0.0064) followed by Tukey’s multiple comparisons test.
(TIF)
S2 Fig. Sorbitol does not cause the formation of insoluble endogenous full-length TDP-43
or its 35 kDa cleavage fragment. HeLa cells were treated with 1 mM H2O2, 1 μM thapsigarin
(TH) or 0.4 M D-sorbitol. Full-length TDP-43 and its 35 kDa cleavage product (marked with
asterisk) were detected in the RIPA-soluble protein fraction (R), but not in the RIPA-insoluble,
urea-soluble fraction (U). Arrowhead denotes unspecific band.
(TIF)
S3 Fig. Sorbitol causes caspase-3 activation and TDP-43 cleavage in HeLa, but not in
SH-SY5Y cells. A) HeLa cells and undifferentiated SH-SY5Y cells were treated with 0.5 mM
(SH-SY5Y) or 1 mM (HeLa) hydrogen peroxide (H2O2), 1 μM thapsigargin (TH) or 0.4 M D-
sorbitol. The generation of CTF35 as well as the activation of caspase-3 was observed in HeLa
cells after 1 hour of D-sorbitol treatment, but not in SH-SY5Y cells. B) Prominent formation
of HuR-positive stress granules in SH-SY5Y cells in response to sorbitol (indicated with arrow-
head). Blue = DAPI, green = TDP-43, red = HuR. Scale bar = 30 μm.
(TIF)
S4 Fig. Sorbitol causes the cytoplasmic accumulation of NLS-EGFP. (A) Immunofluores-
cence images of HeLa cells transfected with EGFP fused to a nuclear localization sequence.
After 24 h, cells were treated with DMSO or Z-VAD-FMK for 30 min, followed by regular
medium or 0.4 M sorbitol for 60 min. Scale bar = 20 μm. (B) Quantification of nuclear
NLS-EGFP signal as a proportion of total cellular EGFP signal (N = 3–4). Results represent
mean percentage of nuclear GFP signal ± S.E.M.;  p< 0.05; one-way ANOVA (F2,8 = 7.754,
P = 0.0134) followed by Dunnett’s multiple comparisons test.
(TIF)
S5 Fig. Increase in nuclear TDP-43 and HuR after cessation of sorbitol stress. HeLa cells
were exposed to 0.4 M D-sorbitol for 1 h, then left to recover for 0 min, 15 min or 60 min. (A)
Nuclear TDP-43 and (B) HuR signals were quantified. Results represent mean nuclear immu-
nofluorescence per cell ± SEM;  p< 0.01 (N = 3); one-way ANOVA (TDP-43: F2,6 = 10.34,
P = 0.0114; HuR: F2,6 = 18.72, P = 0.0026) followed by Dunnett’s multiple comparisons test.
(TIF)
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S6 Fig. myc-TDP-43 forms granular pattern under sorbitol stress conditions. TDP-43 was
expressed in HeLa cells for 24 h before sorbitol was added for 1 h. Overexpressed myc-TDP-43
forms a granular staining pattern in the nucleus indicative of protein aggregation both in cells
with (blue rectangle) and without (orange rectangle) cytoplasmic TDP-43 relocalization (WT-
transfected example).
(TIF)
S7 Fig. The A90V variant does not inhibit stress granule formation. HeLa cells were trans-
fected with WT, A90V or M337V TDP-43. After 24 h, cells were either left untreated or were
treated with 0.4 M sorbitol for 1 h. (A) Immunofluorescence staining of transfected HeLa cells
with or without additional sorbitol treatment. Green = myc, red = TDP-43. Arrowheads indi-
cate stress granules. (B), (C) Quantification of proportion of transfected cells with TDP-
43-positive stress granules in control conditions (B) or after sorbitol stress (C). Results repre-
sent mean percentage of transfected cells with TDP-43-positive cytoplasmic granules ± SEM.
one-way ANOVA followed by Tukey’s multiple comparisons test (-Sorbitol: F2,12 = 1.098,
P = 0.365; +Sorbitol: F2,12 = 0.3245, P = 0.729).
(TIF)
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